

# ANTICANCER CHEMOTHERAPY ADMINISTRATION AT HOME : PATIENTS AND ONCOLOGISTS HAPPY !



Matthieu Plichart <sup>1</sup>, Christine Pailler <sup>2</sup>, Yacine Touil <sup>3</sup>, Agnès Delattre <sup>4</sup>, Nicolas Gandrille <sup>5</sup>  
 Fondation Santé Service, Levallois-Perret, France

1- M.D. Research & Innovation 2- M.D. Project Leader oncology 3- Pharmacist Head of Chemotherapy Unit 4- Senior Nurse 5- M.D. Head of Development




## Context:

Our hospital at home has built expertise in administering chemotherapy by organizing the process, training nurses performing administration at home, and securing reconstitution in a dedicated pharmacy unit. The COVID-19 pandemic has greatly accelerated the transfer of the administration of cancer chemotherapy from the traditional hospital to hospitalization at home. Oncologists then needed to free up hospital beds quickly and wanted to protect their immunocompromised patients from contamination by the virus. However, two years after the start of the crisis, this activity, which has reached very high levels, continues to progress.

### A constant raise for 5 years

Days of chemotherapy  
 Santé service/ all HAH in France



### In HAH in France, 7 products make 95 % of administrations

- 5-Fluorouracile
- Atezolizumab
- Avelumab
- Azacitidine
- Bendamustine
- Bevacizumab
- Bléomycine
- Bortezomib
- Brentuximab
- Carfilzomib
- Cetuximab
- Cladribine SC
- Cyclophosphamide
- Cytarabine
- Daratumumab SC
- Durvalumab
- Eribuline
- Etoposide
- Gemcitabine
- Isatuximab
- Methotrexate
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Pemetrexed
- Pertuzumab
- Pertuzumab-Trastuzumab
- Rituximab SC
- Topotécan
- Trastuzumab IV
- Trastuzumab SC
- Trastuzumab-Emtansine
- Arsenic trioxide
- Vinblastine
- Vincristine
- Vindésine
- Vinorelbine



## We conducted 3 studies of feasibility and satisfaction of new chemotherapies at home :

### Feasibility and satisfaction of TRASTUZUMAB SC (2017)

- 134 breast cancer patients
- 100 % administrations < 1 hour
- No adverse event for 41% of patients
- Adverse events most often local (pain, inflammation at injection point)


### Feasibility of PERTUZUMAB IV + TRASTUZUMAB SC (2021)

- 49 breast cancer patients
- 369 administrations in HAH
- 92% duration < 1 hour
- Tolerance In HAH ≈ in hospital
- 1 single administration had to be stopped for nausea and pain

### Feasibility and satisfaction of DARATUMUMAB SC (2021)


- 48 patients suffering from multiple myeloma
- 159 administrations in HAH
- Mean duration of administration 40 min
- Excellent immediate tolerance
- No severe adverse event

### HAH Santé Service : types of cancer (2023)



3 areas make 80 % of administrations

### Patient preference for administration



79% of patients prefer administration in HAH rather than in day hospital

Most patients find it practical, facilitating the life



## Conclusions:

Subject to compliance with specifications concerning the duration of administration, the immediate tolerance and the shelf life of the products, the transfer of chemotherapy to HAH is possible on many products. It is popular with patients, with the most frequently mentioned aspects of time savings and fatigue. The activity is consequently raising strongly, demanding an adaptation of our organisation. We are building new facilities for our internal pharmacy and designing a nurse platform aimed to follow-up the patients between the recurrent administrations of chemotherapy in HAH.